Experiments in Mice Demonstrate Possibility of Inducing Biomarker Release to Detect Early Cancers

Feb 24, 2015

|

Premium

NEW YORK (GenomeWeb) – Researchers from Stanford University have demonstrated in mice a technique for inducing tumors to release a detectable biomarker that they hope can be developed into a method for early cancer detection in humans.

The study, published this week in Proceedings of the National Academy of Sciences, was a proof of principle that the team's approach could distinguish mice implanted with human melanoma cells from those without.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Featured White Papers

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Discovering Neuronal Cell Types

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

04

Featured Webinar

Software Tools for NGS-Based Diagnosis of CFTR-Related Diseases in Routine Practice

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Main menu